Chemomab Therapeutics (CMMB) Stock Price, Quote, News & History | Benzinga

Chemomab Therapeutics Ltd (CMMB) Stock Price, Quote, News & History

CMMBNASDAQ

Trade with Public

Trade with Public

$1.92

0.021.05%

At close: Aug 12, 5:00 PM EST

$1.90

-0.02-1.04%

After Hours: 4:16 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Stock Report

Key Statistics

Open

$1.92

Close

$1.92

Volume / Avg.

33.46K / 130.06K

Day Range

$1.87 - $2.04

52 Wk Range

1.35 - 4.12

Market Cap

$13.92M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

62

Short Interest

2.18%

Days to Cover

2.16

Recent Chemomab Therapeutics Ltd News

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.

Vandana Singh

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Avi Kapoor

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.

Vandana Singh

What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

Vandana Singh

Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-

Investing Cash Flow (TTM)

-

Financing Cash Flow (TTM)

-

Free Cash Flow (TTM)

-

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.63M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.31

Earnings Yield % (TTM)

-58.64%

Earnings Yield % (FWD)

-28.52%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.46

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$5.91M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.92

Close

$1.92

Volume / Avg.

33.46K / 130.06K

Day Range

$1.87 - $2.04

52 Wk Range

1.35 - 4.12

Market Cap

$13.92M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

62

Short Interest

2.18%

Days to Cover

2.16

About

Sector

Health Care

Industry

Biotechnology

Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that target...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Chemomab Therapeutics (CMMB) stock?

A

You can purchase shares of Chemomab Therapeutics (NASDAQ:CMMB) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Chemomab Therapeutics (CMMB) competitors?

A

Other companies in Chemomab Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Chemomab Therapeutics (CMMB) stock?

A

Chemomab Therapeutics has a consensus price target of $13.00.

Q

What is the current price for Chemomab Therapeutics (CMMB)?

A

The stock price for Chemomab Therapeutics (NASDAQ: CMMB) is $1.9 last updated August 12, 2026 at 4:16 PM EDT.

Q

Does Chemomab Therapeutics (CMMB) pay a dividend?

A

There are no upcoming dividends for Chemomab Therapeutics.

Q

When is Chemomab Therapeutics (NASDAQ:CMMB) reporting earnings?

A

Chemomab Therapeutics does not have any upcoming earnings scheduled.

Q

Is Chemomab Therapeutics (CMMB) going to split?

A

There is no upcoming split for Chemomab Therapeutics.

Q

What sector and industry does Chemomab Therapeutics (CMMB) operate in?

A

Chemomab Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.